Human papillomavirus vaccine may reduce the rate of oral HPV infections in young adults by as much as 88 percent, studies suggest. However, given the vaccine’s low rate of uptake in the U.S.—especially in males—the impact of the vaccine on oral HPV infections remains low.
LSU Health New Orleans was awarded a five-year, $3.1 million grant from the National Institute of Dental and Craniofacial Research.
